© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Cancer Answers is hosted by Dr. Anees Chagpar, Associate Professor of Surgical Oncology and Director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital, and Dr. Francine Foss, Professor of Medical Oncology. The show features a guest cancer specialist who will share the most recent advances in cancer therapy and respond to listeners questions. Myths, facts and advances in cancer diagnosis and treatment are discussed, with a different focus eachweek. Nationally acclaimed specialists in various types of cancer research, diagnosis, and treatment discuss common misconceptions about the disease and respond to questions from the community.Listeners can submit questions to be answered on the program at canceranswers@yale.edu or by leaving a message at (888) 234-4YCC. As a resource, archived programs from 2006 through the present are available in both audio and written versions on the Yale Cancer Center website.

FDA Rejects Inhaled Insulin Treatment

http://cptv.vo.llnwd.net/o2/ypmwebcontent/Chion/2011_01_20_hj%20110120%20mannkind.mp3

Federal regulators have rejected a new inhaled insulin treatment from drug maker MannKind. The diabetes treatment was due to have been manufactured in Danbury. 

The Food and Drug Administration ruled Wednesday that it needs two more clinical trials before it can once again consider approving Afrezza, an inhaled form of insulin. This means a further delay of at least a year. California-based MannKind had invested in a plant in Danbury to make the treatment once it had permission to bring it to market, and much of the preparation of Afrezza for FDA approval took place at the site.

The company’s shares fell more than 40% on the Nasdaq in after hours trading. Entrepreneur Alfred Mann has invested more than $900 million of his personal fortune into the development of the drug delivery system. It’s the latest setback for this type of insulin treatment. Pfizer dropped  development of its version, Exubera, in 2007, having spent $3 billion on the treatment.

Harriet Jones is Managing Editor for Connecticut Public Radio, overseeing the coverage of daily stories from our busy newsroom.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content